bed wt. 25 mg, volume 10 mL , (LRC), pk of 50
A MIP phase developed and optimized for the selective extraction of chloramphenicol in biological matrices.
Chloramphenicol is a broad-spectrum antibiotic that is currently banned by a number of countries including the EU, the US, and Canada. This MIP phase and associated method offer a simple, efficient, and highly selective extraction method for quantiting chloramphenicol in food products and biological matrices. Detection limits well below the minim required performance limit (MPRL) are achieved consistently.
Features and Benefits
• Highly selective SPE for trace analysis in complex matrices
• Achieve lower detection limits
• Significant time and cost savings
• Improved MS-compatibility
SupelMIP SPE phases were developed by MIP Technologies AB, which is one of the leading authorities and commercial pioneers of molecular imprinted polymers for process scale separations, analytical chromatography, and sample preparation.
The SupelMIP SPE line consists of highly cross-linked polymers that are engineered to extract a single analyte of interest or a class of structurally related analytes with an extremely high degree of selectivity. This is possible because selectivity is introduced during MIP synthesis in which a template molecule, designed to mimic the analyte, guides the formation of specific cavities or imprints that are sterically and chemically complementary to the analyte(s) of interest.
By careful design of the imprinting site, either by molecular modeling, experimental design, or screening methods, the binding cavities can be engineered to offer multiple interaction points with the analyte(s) of interest. This leads to a stronger interaction between the solid-phase and the analyte(s). As a consequence, harsher wash conditions can be tolerated during SPE methodology resulting in cleaner extracts. Because extraction selectivity is significantly improved, lower background is observed allowing analysts to achieve lower limits of detection.
supelMIP is a trademark of Sigma-Aldrich Biotechnology LP and Sigma-Aldrich Co.